ZOMETA® – Threat of SREs From Bone Metastases Increases in Multiple Myeloma Extend Survival

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

About ZOMETA: defend against SREs across a broad range of tumour types

Page

1 2

As new treatments extend survival, the threat of SREs increases

The median survival for patients with multiple myeloma is nearly 4 years⁴
In patients with multiple myeloma and osteolytic disease, the median time to first SRE
is only 9 months⁵

Median time to first SRE vs median survival in multiple myeloma^4,5

*Median survival for patients diagnosed after 1996.

Page

1 2

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.